CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05665062
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:38.682116+00:00
Published At: 2025-04-06T00:00:00+00:00
Record Updated At: 2025-04-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["CLL/SLL", "NHL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Large B-cell Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-06"
protocolSection.identificationModule.nctId: "NCT05665062"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.